Full Text:   <2483>

CLC number: R979.1

On-line Access: 

Received: 2004-10-12

Revision Accepted: 2004-10-23

Crosschecked: 0000-00-00

Cited: 0

Clicked: 6236

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2005 Vol.6 No.1 P.1-3

http://doi.org/10.1631/jzus.2005.B0001


On dendritic cell-based therapy for cancers


Author(s):  Morikazu Onji, Sk. Md. Fazle Akbar

Affiliation(s):  Third Department of Internal Medicine, School of Medicine, Ehime University, Ehime, Japan

Corresponding email(s):   akbar@m.ehime-u.ac.jp

Key Words:  Dendritic cells, Cancer immunology, DC-based therapy, Safety, Efficacy, Animal model of cancers, Human cancers


Share this article to: More |Next Article >>>

Morikazu Onji, Sk. Md. Fazle Akbar. On dendritic cell-based therapy for cancers[J]. Journal of Zhejiang University Science B, 2005, 6(1): 1-3.

@article{title="On dendritic cell-based therapy for cancers",
author="Morikazu Onji, Sk. Md. Fazle Akbar",
journal="Journal of Zhejiang University Science B",
volume="6",
number="1",
pages="1-3",
year="2005",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.2005.B0001"
}

%0 Journal Article
%T On dendritic cell-based therapy for cancers
%A Morikazu Onji
%A Sk. Md. Fazle Akbar
%J Journal of Zhejiang University SCIENCE B
%V 6
%N 1
%P 1-3
%@ 1673-1581
%D 2005
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2005.B0001

TY - JOUR
T1 - On dendritic cell-based therapy for cancers
A1 - Morikazu Onji
A1 - Sk. Md. Fazle Akbar
J0 - Journal of Zhejiang University Science B
VL - 6
IS - 1
SP - 1
EP - 3
%@ 1673-1581
Y1 - 2005
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2005.B0001


Abstract: 
dendritic cells (DCs), the most prevalent antigen-presenting cell in vivo, had been widely characterized in the last three decades. DCs are present in almost all tissues of the body and play cardinal roles in recognition of microbial agents, autoantigens, allergens and alloantigen. DCs process the microbial agents or their antigens and migrate to lymphoid tissues to present the antigenic peptide to lymphocytes. This leads to activation of antigen-specific lymphocytes. Initially, it was assumed that DCs are principally involved in the induction and maintenance of adaptive immune responses, but now it is evident that DCs also have important roles in innate immunity. These features make DCs very good candidates for therapy against various pathological conditions including malignancies. Initially, DC-based therapy was used in animal models of cancers. Data from these studies inspired considerable optimism and DC-based therapies was started in human cancers 8 years ago. In general, DC-based therapy has been found to be safe in patients with cancers, although few controlled trials have been conducted in this regard. Because, the fundamentals principles of human cancers and animal models of cancers are different, the therapeutic efficacy of the ongoing regime of DC-based therapy in cancer patients is not satisfactory. In this review, we covered the various aspects that should be considered for developing better regime of DC-based therapy for human cancers.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1] Akbar, S.M.F., Murakami, H., Horiike, N., Onji, M., 2004a. Dendritic cell-based therapies in the bench and the bed sides. Curr Drug Targets Allergy Infection, 3:305-310.

[2] Akbar, S.M.F., Furukawa, S., Onji, M., Muarta, Y., Niya, T., Kanno, S., Murakami, H., Horiike, N., 2004b. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res, 29:136-141.

[3] Byrne, S.C., Hallyday, G.M., 2002. Dendritic cells making progress with cancer vaccination. Immunol Cell Biol, 80:520-530.

[4] Kumagi, T., Akbar, S.M.F., Horiike, N., Onji, M., 2003. Increased survival and decreased tumor size due to intratumoral injection of ethanol followed by administration of immature dendritic cells. Int J Oncol, 23:945-955.

[5] Onji, M., 2004. Dendritic Cells in Clinics. Springer, Tokyo, Japan.

[6] Schuler, G., Schulre-Thurner, B., Steinman, R.M., 2003. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol, 15:138-147.

[7] Steinman, R.M., 1991. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol, 9:271-296.

[8] Steinman, R.M., Cohn, Z.A., 1973. Identification of a novel cell type in the peripheral lymphoid organs of mice. 1. Morphology, quantification, tissue distribution. J Exp Med, 137:1142-1162.

[9] Steinman, R.M., Dhopadkar, M., 2001. Active immunization against cancer and dendritic cells; the near future. Int J Cancer, 94:459-473.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE